Mineralys Therapeutics, Inc. MLYS Net Operating Loss Carryforwards
Net Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal.
The official record: Mineralys Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s net operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s net operating loss carryforwards?
- Mineralys Therapeutics, Inc. (MLYS) reported net operating loss carryforwards of $59.5M in Q4 2025.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s net operating loss carryforwards?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s net operating loss carryforwards has grown at a 123.9% compound annual growth rate (CAGR), from $5.3M to $59.5M.
- What does net operating loss carryforwards mean?
- These are tax assets representing losses that can be used to reduce taxable income in future periods. They provide a potential future tax shield, improving cash flow by lowering future tax payments. Investors monitor these to estimate the duration and magnitude of potential tax savings.